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Abstract: Human biomonitoring of plasma and urinary levels of nicotine, cotinine, and  
3′-hydroxycotinine was conducted after daily cigarette smoking in a population of 92 male 
Japanese smokers with a mean age of 37 years who had smoked an average of 23 cigarettes 
per day for 16 years. Members of the population were genotyped for the   
nicotine-metabolizing enzyme cytochrome P450 2A6 (CYP2A6).  The mean levels of 
nicotine, the levels of its metabolites cotinine and 3′-hydroxycotinine, and the sum of these 
three levels in subjects one hour after smoking the first cigarette on the sampling day  
were 20.1, 158, 27.7, and 198 ng/mL in plasma and 846, 1,020, 1,010, and 2,870 ng/mL in 
urine under daily smoking conditions.  Plasma levels of 3'-hydroxycotinine and urinary 
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levels of nicotine and 3 ′ -hydroxycotinine were dependent on the CYP2A6  phenotype 
group, which was estimated from the CYP2A6 genotypes of the subjects, including those 
with whole gene deletion. Plasma cotinine levels were significantly correlated with the 
number of cigarettes smoked on the day before sampling (r = 0.71), the average number of 
cigarettes smoked daily (r = 0.58), and the Brinkman index (daily cigarettes × years, r = 
0.48) under the present conditions. The sum of nicotine, cotinine, and 3′-hydroxycotinine 
concentrations in plasma showed a similar relationship to that of the plasma cotinine 
levels.  Urinary concentrations of cotinine and the sum of nicotine metabolite 
concentrations also showed significant correlations with the plasma levels and the previous 
day’s and average cigarette consumption. The numbers of cigarettes smoked per day by 
two subjects with self-reported light smoking habits were predicted by measuring the 
urinary cotinine concentrations and using linear regression equations derived from above-
mentioned data. These results indicate that biomonitoring of the urinary cotinine 
concentration is a good, easy-to-use marker for plasma levels of cotinine and the sum of 
nicotine metabolites in smokers independent of genetic polymorphism of CYP2A6. 
Keywords:  cytochrome P450;  CYP2A6;  3′-hydroxycotinine;  genetic polymorphism; 
smoking index; biomarker 
 
1. Introduction 
Conventional cigarette smoking and environmental tobacco smoke have significant health   
effects [1-4]. Smoking is considered to cause cancer, stroke, and heart disease and also to have a close 
relationship with the occurrence of gastric ulcers, periodontal disease, sudden infant death syndrome, 
and metabolic syndrome [5-8]. Levels of cotinine, a metabolite of nicotine [9-11], in the blood track 
with exposure to tobacco smoke [1]. Promoting smoking cessation should therefore be a major priority 
in all countries [12] and for all health professionals in all clinical settings; however, it has been pointed 
out that in 2007 39.9% of Japanese men were current smokers [13]. It has been reported that even light 
smokers (1–10 cigarettes/day) have some increased risk of adult mortality [14].  Against this 
background, it has been reported that blood cotinine levels for nonsmokers in the United States 
population have decreased by about 70% in the past 15 years, indicating that public health 
interventions to reduce exposure have been successful (http://www.cdc.gov/exposurereport/), but such 
information in other groups or countries is limited [15,16].  Nicotine metabolite (cotinine   
and 3′-hydroxycotinine) concentrations in plasma and/or expired carbon monoxide have been 
examined as validated biomarkers of self-reported cigarette numbers associated with nicotine-
metabolizing enzymes cytochrome P450 2A6 (CYP2A6) and CYP2B6 genotypes [17,18]. 
We reported that white blood cell counts are sensitive biomarkers for smoking exposures and   
time-dependent recovery in healthy volunteers, and such data might be useful in education and in 
monitoring cigarette smoking and cessation [3]. The aim of the present study was to carry out a 
biomonitoring approach using nicotine and its primary and secondary metabolites, which are widely 
used as biomarkers for tobacco smoke in Japanese males. We report herein that the biomonitoring of Int. J. Environ. Res. Public Health 2010, 7                 
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cotinine in the urine is a good, easy-to-use marker for plasma levels of the sum of nicotine metabolites 
in Japanese smokers independent of genetic polymorphism of nicotine-metabolizing enzyme, CYP2A6. 
The number of cigarettes smoked per day in subjects with light smoking habits could also be predicted 
by measuring the urinary cotinine concentrations and using linear regression equations established in 
this study. 
2. Experimental Section 
2.1. Nicotine and Cotinine Determinations in Biological Samples from Male Smokers 
This study was approved by the ethics committee of Hokkaido University and Showa 
Pharmaceutical University.  Nicotine, cotinine (Wako Pure Chemicals, Osaka, Japan), and   
3′-hydroxycotinine (Sigma-Aldrich, St. Louis, MO, USA) were used as standards. A total of 92 male 
Japanese smokers were recruited and were asked to provide information on the numbers of cigarettes 
smoked daily (Table 1). In separate experiments, two male self-reported light smokers (Subjects A and 
B, 23 and 25 years old, respectively) were recruited in an attempt to predict the level of smoking based 
on the first cohort study. Blood and urine samples from individual subjects were obtained 1 hour after 
smoking the first cigarette of the morning and were diluted 10 times with water. Conjugated nicotine 
and its metabolites in biological fluid samples were treated with β-glucuronidase (Wako).  
Table 1. Characteristics of 92 male Japanese smokers and their smoking behavior. 
 
Mean (95% CI)  Median 
95th 
percentile 
Range 
Age 
Number of cigarettes smoked 
on the day before sampling 
Average number of cigarettes 
smoked per day 
Brinkman index (daily 
cigarettes × years) 
Years of smoking  
37 (35–39) 
17 (15–20) 
 
23 (21–25) 
 
382 (312–452) 
 
16 (14–17) 
38 
20 
 
20 
 
300 
 
16 
51 
40 
 
40 
 
1160 
 
31 
25–57 
0–60 
 
0.5–60 
 
7–1550 
 
2–38 
Nicotine and its metabolite concentrations in these samples were  measured by a liquid 
chromatography/mass spectrometry (LC/MS) system [18].  An LCQ Duo mass analyzer (Thermo 
Fisher Scientific, Yokohama, Japan) equipped with Xcalibur software was operated in electrospray 
positive ionization mode and was directly coupled to an Agilent 1100 system (Agilent Technology, 
Tokyo, Japan) with an octadecylsilane column (XBridge, 3.5 µm, 2.1 mm × 150 mm, Waters, Tokyo, 
Japan). To tune the mass spectrometer, the cone voltage was optimized to maximize the intensity of 
the precursor ions for nicotine (m/z = 163), cotinine (m/z = 177), and 3′-hydroxycotinine (m/z = 193). 
The collision energy was then adjusted to optimize the signal. Typical tuning conditions were as 
follow: capillary temperature, 225 °C; cone voltage, 25 V; ion spray voltage, 4.5 kV; and collision 
energy for nicotine, cotinine, and 3 ′ -hydroxycotinine, 28, 30, and 30 kV, respectively, at sheath and 
aux gas (N2) flow rates of 35 and 5 arbitrary units, respectively. The gradient mobile phase consisted Int. J. Environ. Res. Public Health 2010, 7                 
 
 
2956 
of 0.01% (v/v) ammonia and methanol; 0–0.5 min with 5% methanol (v/v) in 0.01% (v/v) ammonia; 
0.5–3.0 min with 5%–16% methanol (v/v); 3–6 min with 16%–90% methanol (v/v); 6–12 min   
with 90%–5% methanol (v/v); 12–17 min with 5% methanol (v/v), at a flow rate of 0.20 mL/min. 
2.2. CYP2A6 Genotyping 
Genotyping of CYP2A6 was carried out using genomic DNA isolated from blood samples [19,20]. 
Subjects were classified into four phenotype groups according to the CYP2A6 genotypes. Group 1 was 
made up of subjects carrying CYP2A6*1/*1 (wild-type). Group 2 contained subjects heterozygous for 
the wild-type allele (CYP2A6*1/*4, CYP2A6*1/*7, CYP2A6*1/*9,  or  CYP2A6*1/*10). Group 3 
consisted of subjects carrying CYP2A6*4/*7, CYP2A6*4/*9, CYP2A6*4/*10, CYP2A6*7/*7, 
CYP2A6*7/*9, CYP2A6*7/*10,  CYP2A6*9/*9,  CYP2A6*9/*10,  or  CYP2A6*10/*10.  Group 4 
contained subjects homozygous for the CYP2A6  deletion allele (CYP2A6*4/*4), according to our 
previous reports [20,21]. 
3. Results and Discussion 
The subject population consisted of 92 male Japanese smokers with a mean age of 37 years who had 
smoked an average of 23 cigarettes per day for 16 years (Table 1). Histograms of the concentrations of 
nicotine and its metabolites in plasma samples taken from these smokers one hour after smoking the 
first cigarette on the sampling day are shown in Figure 1. From the same data, the mean plasma levels 
of nicotine, its metabolites cotinine and 3 ′ -hydroxycotinine, and the sum of the levels of these three 
compounds in the study population were 20.1, 158, 27.7, and 198 ng/mL, respectively (Table 2).  
The 95th percentile values of nicotine, cotinine, 3 ′ -hydroxycotinine, and the sum were 33.5, 374, 89.1,  
and 446 ng/mL, respectively. Similar histograms of nicotine and its metabolite concentrations in urine 
samples are shown in Figure 2 at 1 hour after smoking the first cigarette on the sampling day; the mean 
and 95th percentile values of nicotine, cotinine, 3 ′ -hydroxycotinine, and the sum were 846, 1,020, 
1,010, and 2,870 ng/mL, and 3,540, 2,450, 3,060, and 7,470 ng/mL, respectively (Table 2). 
Plasma levels of 3 ′ -hydroxycotinine  (Figure 3C) and urinary levels of nicotine (Figure  4A)  
and 3′-hydroxycotinine (Figure 4C) were dependent on the CYP2A6 phenotype group estimated from 
the subjects’ CYP2A6  genotypes, including those with impaired function or whole gene deletion 
mutations. Concentrations of the secondary metabolite 3 ′ -hydroxycotinine in plasma and urine were 
significantly lower in expected poor metabolizers; however, urinary unmetabolized nicotine levels in 
the same group were high. Cotinine levels in plasma (Figure 3B) and urine (Figure 4B) samples were 
not affected by the CYP2A6 phenotype under daily cigarette smoking conditions. The sum of the 
metabolite concentrations in plasma (Figure 3D) and in urine (Figure 4D) were also independent of the 
CYP2A6  phenotype. Urinary concentrations of cotinine and the sum of nicotine metabolites also 
showed significant correlations (r = 0.75 and 0.65) with their plasma levels (Figure 5), indicating that 
urinary cotinine concentration was a good marker for plasma levels of nicotine metabolites. Int. J. Environ. Res. Public Health 2010, 7                 
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Figure 1. Plasma levels of nicotine and its metabolites in 92 male Japanese smokers 1 hour 
after smoking the first cigarette on the sampling day.  Concentrations of nicotine (A), 
cotinine (B), and 3 ′ -hydroxycotinine (C) were determined by LC/MS/MS. The sum (D) 
indicates the total concentration of nicotine, cotinine, and 3 ′ -hydroxycotinine in each 
individual subject.  Concentrations of 3 ′ -hydroxycotinine were lower than the limit of 
detection in seven subjects. 
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Figure 2. Urinary levels of nicotine and its metabolites in 91 male Japanese subjects 1 
hour after smoking the first cigarette on the sampling day. Concentrations of nicotine (A), 
cotinine (B), and 3′-hydroxycotinine (C) were determined by LC/MS/MS. The sum (D) 
indicates the total concentration of nicotine, cotinine, and 3 ′ -hydroxycotinine in each 
individual subject. A urine sample was not obtained from one subject.  
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Table 2.  Plasma and urine levels of nicotine and its metabolites in 92 male Japanese 
subjects 1 hour after smoking the first cigarette of the day. 
 
Mean (95% CI) 
(ng/mL) 
Median 
(ng/mL) 
95th 
percentile 
(ng/mL) 
Range 
(ng/mL) 
Plasma levels 
Nicotine 
Cotinine 
3′-Hydroxycotinine 
Sum 
a 
Urine levels 
Nicotine 
Cotinine 
3′-Hydroxycotinine 
Sum 
a 
 
20.1 (18.5–21.7) 
158 (134–182) 
27.7 (21.6–33.7) 
198 (169–227) 
 
846 (648–1040) 
1,020 (837–1120) 
1,010 (783–1240) 
2,870 (2350–3340) 
 
17.8 
146  
18.7 
183  
 
561 
862 
644 
2420 
 
33.5 
374  
89.1 
446  
 
3540 
2450 
3060 
7470 
 
8.10–51.8 
3.52–556 
< 1–168 
15.0–763 
 
15.7–4400 
15.8–4780 
3.84–5780 
46.8–14800 
a Nicotine, cotinine, and 3′-hydroxycotinine concentrations were combined for individual subjects. 
Figure  3.  Plasma levels of nicotine and its metabolites in male Japanese smokers 
phenotyped for the CYP2A6  gene.  Individuals were grouped in either group 1, 
CYP2A6*1/*1 (n = 19); group 2, CYP2A6*1/*4, *7, *9, *10 (n = 42); group 3, CYP2A6*4, 
*7, *9, *10/*7, *9, *10 (n = 24); and group 4, CYP2A6*4/*4 (n = 2). Information on 
phenotype was not obtained from five subjects. Circles represent individual data and lines 
denote group means. ***, Significantly different compared with group 1 (p < 0.001). 
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Figure  4.  Urinary levels of nicotine and its metabolites in male Japanese smokers 
phenotyped for the CYP2A6 gene. See legend of Figure 3 for further details. 
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Figure 5. Correlation between individual urinary and plasma levels of cotinine (A) and the sum (B). 
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Plasma cotinine levels were significantly correlated with the number of cigarettes smoked on the 
day before sampling (Figure 6A, r  = 0.71), the average number of cigarettes smoked per day   
(Figure 6B, r = 0.58), and the Brinkman index (Figure 6C, r = 0.48) under the present conditions  
(n = 91–92). Int. J. Environ. Res. Public Health 2010, 7                 
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Figure 6. Relationship between plasma levels of cotinine (A,B,C) and sum (D,E,F) and 
three kinds of smoking status indicators. Information on the number of cigarettes smoked 
on the day before sampling and the Brinkman index was not obtained from one subject. 
The solid line represents the linear regression. 
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The sum of nicotine, cotinine, and 3 ′ -hydroxycotinine concentrations in plasma showed similar 
relationships (Figures  6D–F,  r  = 0.52–0.69).  The relationship between urinary concentrations of 
cotinine showed low but significant correlation coefficients with the number of cigarettes smoked on 
the day before sampling (Figure  7A,  r  = 0.52), the average number of cigarettes smoked per   
day (Figure  7B,  r  = 0.47), and the Brinkman index (Figure  7C,  r  = 0.24) under the present   
conditions  (n = 91–92).  Similar correlation coefficients were seen for the sum of nicotine  
metabolites (Figures 7D–F).  
Urinary cotinine excretion in self-reported light smokers was also measured (Table 3). From the 
slopes of the good linear regression lines shown in Figures 5A and 5B, plasma cotinine levels and  
the sum of nicotine metabolites were estimated by dividing the urinary cotinine concentration   
by 6.13 (r = 0.75) or the sum of metabolite concentrations in urine by 13.7. The number of cigarettes 
smoked on the previous day was then predicted by dividing the estimated plasma cotinine level by 8.24 
(the slope in Figure 6A, r = 0.71) or the sum of metabolites in plasma by 10.4 (the slope in Figure 6D). 
When the urinary cotinine concentration was used, the actual number of cigarettes smoked on the 
preceding day as obtained by interview was able to be predicted using the positive relationships found 
in the present study.  Int. J. Environ. Res. Public Health 2010, 7                 
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Figure 7. Relationship between urinary levels of cotinine (A,B,C) and sum (D,E,F) and 
three kinds of smoking status indicators. See legend of Figure 6 for further details.  
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Table 3. Estimated number of cigarettes smoked on the day before sampling by 
biomonitoring of urinary cotinine concentrations in two subjects who were light smokers.  
  Subject 
  A  B 
Urinary concentration (ng/mL) 
Cotinine 
Nicotine 
3′-Hydroxycotinine  
Sum 
Number of cigarettes smoked on the day before sampling 
Predicted numbers based on cotinine concentration 
a 
Predicted numbers based on the sum of concentrations 
b 
Interviewed (self-reported) numbers 
 
136  
79 
25  
240  
 
3  
2  
3  
 
396  
29 
432  
857  
 
8  
6  
10  
a From the slope of the linear regression line shown in Figure 5A, the plasma cotinine level was 
estimated by dividing the urinary cotinine concentration by 6.13. The number of cigarettes smoked 
on the day before sampling was predicted by dividing the estimated plasma cotinine level by 8.24 
(the slope in Figure 6A).  
b From the slope of the linear regression line shown in Figure 5B, the nicotine equivalent (sum) in 
plasma was calculated by dividing the sum in urine by 13.7. The number of cigarettes smoked on 
the day before sampling was predicted by dividing the estimated sum in plasma by 10.4 (the slope 
in Figure 6D).  
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It has been reported that single cigarette smoking might be a tool for CYP2A6 phenotyping in those 
affected by loss-of-function gene mutations [22].  However, under daily smoking conditions, 
cumulative cotinine concentrations in the urine or plasma may not be affected by the CYP2A6 
genotypes, as shown in Figures 3B and 4B, which is consistent with our findings that nicotine could be 
metabolized by CYP2A6  and  CYP2B6  in human liver microsomes [23].  Roles of exptrahepatic 
CYP2A13 [24,25] could not be ruled out in this nicotine metabolism. Significant, but relatively low 
correlation coefficients between the concentration of nicotine metabolites in biological fluids and the 
Brinkman index (number of cigarettes smoked × years) were also seen in the present study 
(Figures 6 and 7). Cotinine levels may be the best current biomarker for cigarette smoking [16] or 
secondhand smoke exposure [12], as reported previously.  
4. Conclusions 
Smoking is one of the most important behavioral risk factors for premature death worldwide [14]. 
The present results indicate that biomonitoring of the urinary cotinine concentration is a good,   
easy-to-use marker for plasma levels of cotinine and is convenient for predicting the number of 
cigarettes smoked on the preceding day under daily smoking conditions, independent of genetic 
polymorphism of CYP2A6. 
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